CANNABIDIOL: THE USE OF CBD AS A PHARMACOLOGICAL RESOURCE

Abstract

Cannabidiol (CBD) is a non-psychoactive compound derived from Cannabis sativa, widely studied for its pharmacological properties and potential therapeutic benefits. This descriptive study, with a qualitative approach, was based on a literature review to analyze the role of the clinical pharmacist in the pharmacotherapeutic monitoring of patients undergoing treatment with cannabidiol. Evidence shows that CBD has antioxidant, anti-inflammatory, anxiolytic, neuroprotective, and anticonvulsant effects, with proven efficacy in pathologies such as refractory epilepsy, neurodegenerative diseases, anxiety disorders, and Autism Spectrum Disorder (ASD). The regulation of the medicinal use of Cannabis sativa in Brazil has evolved significantly after the publication of ANVISA's RDC No. 327/2019, which defined standards for the prescription, production, and dispensing of products containing cannabinoids. In this context, the clinical pharmacist plays an essential role, acting from the assessment of therapeutic appropriateness to the monitoring of adherence and identification of adverse reactions, ensuring the rational and safe use of therapy. Despite advances, challenges persist, such as the high cost of medications, the limitation of national production, the lack of standardized clinical protocols, and the social stigma related to the plant. It is concluded that cannabidiol represents a promising pharmacological resource, whose consolidation depends on the strengthening of public policies, the expansion of access, and the recognition of the pharmacist as a fundamental agent in the safety and efficacy of treatment.